Huilian Wang1, Xi Lu2, Xudong Yang1, Qilan Ning1. 1. Department of Genetics and Molecular Biology, School of Medicine, Xi'an Jiaotong UniversityXi'an 710061, Shaanxi, P. R. China; Key Laboratory of Environment and Genes Related to Diseases (Xi'an Jiaotong University), Ministry of EducationXi'an 710061, Shaanxi, P. R. China. 2. School of Mechanical Engineering, Xi'an Jiaotong University Xi'an 710049, Shaanxi, P. R. China.
Abstract
BACKGROUND: Chronic hepatitis B virus (HBV) infection remains a major public health problem worldwide. Tenofovir monotherapy or tenofovir-based combination therapy have achieved promising results in the treatment of chronic hepatitis B patients who failed adefovir therapy. OBJECTIVE: The goal of this study was to assess the efficacy of tenofovir monotherapy compared with tenofovir-based combination therapy for treatment of adefovir-experienced chronic hepatitis B (CHB) patients. METHODS: randomized and non-randomized control trials directly comparing tenofovir monotherapy and tenofovir-based combination therapy were searched in PUBMED, MEDLINE, EMBASE database up to April 30, 2015. The data were analyzed with Review Manager (v.5.3). RESULTS: Seven articles (total of 478 patients) met entry criteria. The results found that the rates of undetectable hepatitis B virus DNA levels (64.7% vs. 68.5%, P = 0.58 for 24 weeks; 71.4% vs. 71.7%, P = 0.76 for 48 weeks; 71.6% vs. 73.0%, P = 0.92 for 96 weeks), alanine aminotransferase (ALT) normalization (72.6% vs. 69.2%, P = 0.46 for 48 weeks; 72.8% vs. 75.0%, P = 0.74 for 96 weeks) and hepatitis Be antigen loss (5.0% vs. 0, P = 0.43 for 48 weeks; 16.5% vs. 12.5%, P = 0.43 for 96 weeks) were not significantly different between the TDF alone and the TDF-based group. Moreover, the rate of adverse reactions was also not significantly different between the 2 groups (P = 0.06 for 96 weeks). CONCLUSIONS: TDF monotherapy and TDF-based combination therapy are similarly effective and safe in adefovir-experienced CHB patients after 48 weeks and 96 weeks of antiviral therapy. Nevertheless, large scale randomized control trials should be carried out to elucidate the long-term outcome of TDF treatment.
BACKGROUND:Chronic hepatitis B virus (HBV) infection remains a major public health problem worldwide. Tenofovir monotherapy or tenofovir-based combination therapy have achieved promising results in the treatment of chronic hepatitis Bpatients who failed adefovir therapy. OBJECTIVE: The goal of this study was to assess the efficacy of tenofovir monotherapy compared with tenofovir-based combination therapy for treatment of adefovir-experienced chronic hepatitis B (CHB) patients. METHODS: randomized and non-randomized control trials directly comparing tenofovir monotherapy and tenofovir-based combination therapy were searched in PUBMED, MEDLINE, EMBASE database up to April 30, 2015. The data were analyzed with Review Manager (v.5.3). RESULTS: Seven articles (total of 478 patients) met entry criteria. The results found that the rates of undetectable hepatitis B virus DNA levels (64.7% vs. 68.5%, P = 0.58 for 24 weeks; 71.4% vs. 71.7%, P = 0.76 for 48 weeks; 71.6% vs. 73.0%, P = 0.92 for 96 weeks), alanine aminotransferase (ALT) normalization (72.6% vs. 69.2%, P = 0.46 for 48 weeks; 72.8% vs. 75.0%, P = 0.74 for 96 weeks) and hepatitis Be antigen loss (5.0% vs. 0, P = 0.43 for 48 weeks; 16.5% vs. 12.5%, P = 0.43 for 96 weeks) were not significantly different between the TDF alone and the TDF-based group. Moreover, the rate of adverse reactions was also not significantly different between the 2 groups (P = 0.06 for 96 weeks). CONCLUSIONS: TDF monotherapy and TDF-based combination therapy are similarly effective and safe in adefovir-experienced CHB patients after 48 weeks and 96 weeks of antiviral therapy. Nevertheless, large scale randomized control trials should be carried out to elucidate the long-term outcome of TDF treatment.
Authors: S J Patterson; J George; S I Strasser; A U Lee; W Sievert; A J Nicoll; P V Desmond; S K Roberts; S Locarnini; S Bowden; P W Angus Journal: Gut Date: 2010-10-29 Impact factor: 23.059
Authors: Yoon-Seon Lee; Dong Jin Suh; Young-Suk Lim; Suk Won Jung; Kang Mo Kim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee; Wangdon Yoo; Soo-Ok Kim Journal: Hepatology Date: 2006-06 Impact factor: 17.425
Authors: Jorg Petersen; Vlad Ratziu; Maria Buti; Harry L A Janssen; Ashley Brown; Pietro Lampertico; Jan Schollmeyer; Fabien Zoulim; Heiner Wedemeyer; Martina Sterneck; Thomas Berg; Christoph Sarrazin; Marc Lutgehetmann; Peter Buggisch Journal: J Hepatol Date: 2011-10-26 Impact factor: 25.083
Authors: Marion G Peters; Janet Andersen; Patrick Lynch; Tun Liu; Beverly Alston-Smith; Carol L Brosgart; Jeffrey M Jacobson; Victoria A Johnson; Richard B Pollard; James F Rooney; Kenneth E Sherman; Susan Swindells; Bruce Polsky Journal: Hepatology Date: 2006-11 Impact factor: 17.425
Authors: Andrea Snow-Lampart; Brandi Chappell; Maria Curtis; Yuao Zhu; Florence Myrick; James Schawalder; Kathryn Kitrinos; Evguenia S Svarovskaia; Michael D Miller; Jeff Sorbel; Jenny Heathcote; Patrick Marcellin; Katyna Borroto-Esoda Journal: Hepatology Date: 2010-12-22 Impact factor: 17.425
Authors: Emmet B Keeffe; Douglas T Dieterich; Steven-Huy B Han; Ira M Jacobson; Paul Martin; Eugene R Schiff; Hillel Tobias; Teresa L Wright Journal: Clin Gastroenterol Hepatol Date: 2006-07-14 Impact factor: 11.382
Authors: Thomas Berg; Fabien Zoulim; Bernd Moeller; Huy Trinh; Patrick Marcellin; Sing Chan; Kathryn M Kitrinos; Phillip Dinh; John F Flaherty; John G McHutchison; Michael Manns Journal: J Hepatol Date: 2013-12-01 Impact factor: 25.083
Authors: Christopher E Westland; Huiling Yang; William E Delaney; Craig S Gibbs; Michael D Miller; Michael Wulfsohn; John Fry; Carol L Brosgart; Shelly Xiong Journal: Hepatology Date: 2003-07 Impact factor: 17.425